Retifanlimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Anal Canal

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the US

Also approved (3)
EU
  • Zynyz in combination with carboplatin and paclitaxel for first-line treatment of adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canalcancernetwork.com
  • Zynyz monotherapy for first-line treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma not amenable to curative surgery or radiation therapy (MAH Incyte Biosciences Distribution B.V.); a squamous cell carcinoma of the anal canal indication was added later
    EMA
Product first approved 2024
JP
  • Treatment of unresectable advanced or recurrent squamous cell carcinoma of the anal canal
Product first approved 2025PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Non-Small Cell Lung Cancer
NCT04203511 · Incyte Corporation
2020-07-31 – 2025-01-31 · Non-small Cell Lung Cancer
What this study did
Squamous Cell Carcinoma of the Anal Canal
Other / comorbidity
NCT06072612 · BriaCell Therapeutics Corporation
2023-12-05 – 2028-06 · Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT04082364 · MacroGenics
2019-09-30 – 2025-03-25 · Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
What this study did
NCT04129320 · MacroGenics
2019-10 – 2022-10 · Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
What this study did
Phase 2 (31)
Merkel Cell Carcinoma
NCT06056895 · University of Washington
2023-11-08 – 2027-04-30 · Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
What this study did
NCT05594290 · Gruppo Oncologico del Nord-Ovest
2022-12-07 – 2026-11 · Merkel Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT03679767 · Incyte Corporation
2019-01-09 – 2022-06-28 · Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma, Metastatic Melanoma, Locally Advanced Renal Cell Carcinoma, Metastatic Clear-Cell Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT07772245 · Polly A. Niravath, MD
2026-12-31 – 2032-12-31 · HER2-addicted Breast Cancer
What this study did
NCT07765836 · Massachusetts General Hospital
2027-01 – 2030-12-31 · Pancreatic Cancer Metastatic
What this study did
NCT04374305 · Scott R. Plotkin, MD, PhD
2020-06-20 – 2030-12-01 · Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
What this study did
NCT06160206 · Academic and Community Cancer Research United
2024-10-02 – 2030-11-30 · Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
What this study did
NCT05177133 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2021-11-05 – 2029-11-04 · Gastric Adenocarcinoma, Esophageal Adenocarcinoma
What this study did
NCT07927998 · Memorial Sloan Kettering Cancer Center
2026-11-04 – 2029-11-04 · Anal Squamous Cell Carcinoma, Anal Cancer, Anal Carcinoma
What this study did
NCT04225039 · University of Pennsylvania
2020-06-23 – 2029-04-30 · Glioblastoma
What this study did
NCT07425054 · Jennifer Dorth
2026-06-19 – 2029-01 · Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
What this study did
NCT06389799 · Lund University Hospital
2024-06-20 – 2028-12-31 · Dedifferentiated Liposarcoma
What this study did
NCT07677579 · Northwell Health
2026-08-30 – 2028-12-30 · Colon Cancer Metastatic
What this study did
NCT05345002 · Stephen Bagley, MD, MSCE
2022-11-16 – 2028-06-01 · Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
What this study did
NCT04968106 · Institut Bergonié
2022-12-07 – 2028-04 · Resectable Sarcoma
What this study did
NCT04438824 · Memorial Sloan Kettering Cancer Center
2020-06-17 – 2027-06 · Well-differentiated/Dedifferentiated Liposarcoma
What this study did
NCT04494009 · Asan Medical Center
2020-09-07 – 2026-12-31 · Esophageal Cancer
What this study did
NCT03532295 · Washington University School of Medicine
2020-04-20 – 2025-10-31 · Glioma, Glioblastoma
What this study did
NCT04445844 · Mridula George, MD
2020-07-13 – 2025-06-30 · Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
What this study did
NCT05359692 · Incyte Biosciences International Sàrl
2023-03-01 – 2025-01-11 · Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT04116073 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-04-09 – 2024-12-03 · Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
What this study did
NCT04949191 · Incyte Corporation
2021-07-08 – 2024-04-11 · Advanced Malignancies
What this study did
NCT05239182 · Anwaar Saeed
2022-01-26 – 2024-02-04 · Pancreatic Adenocarcinoma
What this study did
NCT04586244 · Incyte Corporation
2022-01-14 – 2024-01-29 · Urothelial Carcinoma
What this study did
NCT04231981 · MedSIR
2020-04-28 – 2022-08-26 · Penile Cancer
What this study did
NCT04634825 · MacroGenics
2021-03-17 – 2022-07-29 · Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
What this study did
NCT04776876 · M.D. Anderson Cancer Center
2021-03-01 – 2021-09-02 · Advanced Neuroendocrine Neoplasm, Carcinoid Syndrome
What this study did
Phase 1/2 (14)
Merkel Cell Carcinoma
NCT07472322 · University of Wisconsin, Madison
2026-11 – 2031-05 · Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IV
What this study did
NCT06939036 · Ariceum Therapeutics GmbH
2025-07-01 – 2025-12-31 · Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07219576 · University of California, San Diego
2026-01-08 – 2029-12 · Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
What this study did
NCT03729596 · MacroGenics
2018-11-21 – 2023-03-18 · Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06149481 · National Cancer Institute (NCI)
2024-03-26 – 2030-10-31 · Metastatic Colorectal Cancer
What this study did
NCT07468136 · Mayo Clinic
2026-06-23 – 2030-10-25 · Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
What this study did
NCT06320405 · OHSU Knight Cancer Institute
2024-05-21 – 2029-04-01 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
What this study did
NCT04577014 · Memorial Sloan Kettering Cancer Center
2020-09-29 – 2027-09-29 · Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
What this study did
NCT05455697 · University of Washington
2023-01-26 – 2027-01-05 · Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
What this study did
NCT06873789 · Incyte Corporation
2025-06-30 – 2026-07-29 · Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
What this study did
NCT03328026 · BriaCell Therapeutics Corporation
2018-03-16 – 2026-03-24 · Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
What this study did
NCT02393248 · Incyte Corporation
2015-02-27 – 2021-12-17 · Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN
What this study did
NCT03531632 · MacroGenics
2018-06-04 – 2020-02-08 · Colorectal Cancer Metastatic
What this study did
Phase 1 (20)
Non-Small Cell Lung Cancer
NCT04580485 · Incyte Corporation
2021-02-03 – 2024-01-22 · Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
What this study did
NCT02475213 · MacroGenics
2015-07 – 2021-08-18 · Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
What this study did
NCT03920839 · Incyte Corporation
2019-07-15 – 2019-11-04 · Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
What this study did
Other / comorbidity
NCT06896188 · Anwaar Saeed
2025-09-22 – 2029-12-31 · Pancreatic Adenocarcinoma
What this study did
NCT05743595 · Washington University School of Medicine
2023-10-27 – 2029-03-09 · Unmethylated Glioblastoma
What this study did
NCT05083754 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2022-08-31 – 2029-01 · Glioblastoma Multiforme
What this study did
NCT04470024 · Providence Health & Services
2021-08-05 – 2028-12-31 · Cancer of the Head and Neck
What this study did
NCT06610682 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2025-04-07 – 2028-06-30 · BRAF V600E Mutation
What this study did
NCT04387084 · University of Southern California
2020-08-12 – 2028-03-31 · Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
What this study did
NCT06290622 · University of Alabama at Birmingham
2024-08-30 – 2028-01-31 · Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular
What this study did
NCT06179160 · Incyte Corporation
2024-01-04 – 2027-01-01 · Solid Tumors
What this study did
NCT03522142 · Incyte Corporation
2018-08-27 – 2025-09-10 · Advanced Solid Tumors
What this study did
NCT05440942 · Peter Hosein, MD
2023-01-19 – 2025-05-30 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT04989387 · Incyte Corporation
2021-10-04 – 2024-09-19 · Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
What this study did
NCT03059823 · Incyte Corporation
2016-11-15 – 2024-05-22 · Locally Advanced Solid Tumors, Metastatic Solid Tumors
What this study did
NCT04799431 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2023-05-03 – 2023-05-03 · Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
What this study did
NCT03589651 · Incyte Corporation
2018-08-17 – 2022-11-21 · Unresectable or Metastatic Solid Tumors
What this study did
NCT03406949 · MacroGenics
2018-02-27 – 2022-04-27 · Advanced Solid Tumors
What this study did
NCT03910530 · Incyte Biosciences Japan GK
2019-07-22 – 2021-12-14 · Advanced Solid Tumors, Metastatic Solid Tumors
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Merkel Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Retifanlimab: this drugApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AvelumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT03783078: Objective Response Rate (ORR) (Up to ~34 months): Pembrolizumab 200 mg 49.1 Percentage of participants (95% CI 35.4 to 62.9)
NCT02267603: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (Up to 3 years): Treatment (Pembrolizumab) — Number participants with partial response (PR): 16 Participants; Number participants with complete response (CR): 12 Participants; Combined total participants with either PR or CR: 28 Participants
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
IFx-2.0Phase 2/3Gene therapy / editingInnate immune activation (intralesional plasmid DNA)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(25 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Retifanlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 2Recurrent Glioblastoma, Recurrent WHO Grade 4 GliomaRecruiting
Est. primary completion 2026-11-30 · NCT06160206 · CT.gov ↗
What to watch
December 2026 (1)
Phase 2Esophageal CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04494009 · CT.gov ↗
What to watch
2027 (13)
January 2027 (2)
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-01-01 · NCT06179160 · CT.gov ↗
What to watch
Phase 2Merkel Cell CarcinomaActive not recruiting
Est. primary completion 2027-01-31 · NCT06056895 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm …Recruiting
Est. primary completion 2027-04-01 · NCT06320405 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Well-differentiated/Dedifferentiated LiposarcomaActive not recruiting
Est. primary completion 2027-06 · NCT04438824 · CT.gov ↗
What to watch
Phase 2Glioma, IDH Mutation, Astrocytoma, OligodendrogliomaRecruiting
Est. primary completion 2027-06-01 · NCT05345002 · CT.gov ↗
What to watch
Phase 1BRAF V600E MutationRecruiting
Est. primary completion 2027-06-30 · NCT06610682 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma AdultRecruiting
Est. primary completion 2027-09-29 · NCT04577014 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-10-31 · NCT06149481 · CT.gov ↗
What to watch
December 2027 (4)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07219576 · CT.gov ↗
What to watch
Phase 3Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage CancerRecruiting
Est. primary completion 2027-12 · NCT06072612 · CT.gov ↗
What to watch
Phase 1Cancer of the Head and NeckActive not recruiting
Est. primary completion 2027-12-31 · NCT04470024 · CT.gov ↗
What to watch
Phase 2Dedifferentiated LiposarcomaRecruiting
Est. primary completion 2027-12-31 · NCT06389799 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 1Glioblastoma MultiformeRecruiting
Est. primary completion 2028-01 · NCT05083754 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2028-03-30 · NCT06896188 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Colon Cancer MetastaticNot yet recruiting
Est. primary completion 2028-08-30 · NCT07677579 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Pancreatic Cancer MetastaticNot yet recruiting
Est. primary completion 2028-12-31 · NCT07765836 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 2Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the AnusRecruiting
Est. primary completion 2029-01 · NCT07425054 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Anal Squamous Cell Carcinoma, Anal Cancer, Anal CarcinomaRecruiting
Est. primary completion 2029-11-04 · NCT07927998 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, EpendymomaRecruiting
Est. primary completion 2029-12-01 · NCT04374305 · CT.gov ↗
What to watch
Phase 2HER2-addicted Breast CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07772245 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
Phase 1/2Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma …Recruiting
Est. primary completion 2030-10-25 · NCT07468136 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 1/2Merkel Cell CarcinomaNot yet recruiting
Est. primary completion 2031-05 · NCT07472322 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 March 2026ApprovalEuropean Commission approves Zynyz for advanced SCAC
EU, EC · Source ↗